Rogers (ROG)
(Delayed Data from NYSE)
$109.21 USD
+1.45 (1.35%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $109.31 +0.10 (0.09%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ROG 109.21 +1.45(1.35%)
Will ROG be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ROG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ROG
Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Strong ETF Right Now?
Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Strong ETF Right Now?
ROG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco S&P International Developed Quality ETF (IDHQ) a Strong ETF Right Now?
Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Strong ETF Right Now?
Rogers Corp. (ROG) Tops Q3 Earnings Estimates
Other News for ROG
Roche prepares for business after boom from COVID-related products
Rogers: Short-Term Headwinds Are Likely Temporary
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study